By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lexicon Pharmaceuticals, Inc. 

8800 Technology Forest Place

The Woodlands  Texas  77381-1160  U.S.A.
Phone: 281-863-3000 Fax: 281-863-8088



Company News
Lexicon Pharma (LXRX) Begins Phase 1 Clinical Trial Of Locally-Acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes 1/9/2017 7:49:25 AM
Lexicon Pharma (LXRX) Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes 12/21/2016 11:37:35 AM
Lexicon Pharma (LXRX) Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration With Juvenile Diabetes Research Foundation 12/6/2016 6:34:42 AM
Lexicon Pharma (LXRX) Announces The Establishment Of The Commercial Leadership Team For Telotristat Ethyl 11/21/2016 8:55:55 AM
Lexicon Pharma (LXRX) Acquires Exclusive Rights To Development Candidate For Neuropathic Pain From Its Alliance With Bristol-Myers Squibb (BMY) 11/7/2016 10:23:15 AM
Lexicon Pharma (LXRX) Provides Clinical Pipeline Update And Reports 2016 Third Quarter Financial Results 11/1/2016 9:29:56 AM
Lexicon Pharma (LXRX) Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology 11/1/2016 6:54:54 AM
Lexicon Pharma (LXRX) To Report Third Quarter 2016 Financial Results On November 1, 2016 10/25/2016 9:28:49 AM
Lexicon Pharma (LXRX) Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes 10/25/2016 6:47:34 AM
Lexicon Pharma (LXRX) Announces Agreement To Buy Out Remaining Obligations To Symphony Icon, Inc. 10/5/2016 6:32:37 AM